"Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's drug regulator, it said on Thursday. A 5 MG vial of the drug has been priced at Rs 4,375, while a 2.5 MG vial will cost Rs 3,500.
Global demand for Lilly's diabetes and weight-loss drugs has soared, with the launch presenting a big market opportunity for the U.S.b-ased drug company as India, world's most populous country, is seeing increasing rates of obesity and diabetes.The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India,"" said President and General Manager Winselow Tucker at Lilly India
India has about 101 million people living with diabetes and obesity, a chronic relapsing disease, is a major risk factor for diabetes, Lilly said.
Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weight-loss. It is sold as Zepbound for obesity in the U.S.
CEO David Ricks told Reuters in February last year that Lilly expects to